CCM
Camber Capital Management Portfolio holdings
AUM
$718M
1-Year Est. Return
8.19%
This Fund
S&P 500
1 Year Est. Return
-8.19%
AUM
$718M
AUM Growth
-$885M
(-55%)
Holding
35
Top Buys
| 1 | +$42.6M | |
| 2 | +$39.7M | |
| 3 | +$38.2M | |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.89M |
Top Sells
| 1 | +$121M | |
| 2 | +$106M | |
| 3 | +$87.9M | |
| 4 |
CVS Health
CVS
|
+$78.7M |
| 5 |
PTC Therapeutics
PTCT
|
+$76.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Genmab
GMAB
$17.5B
| – | – |
-50,000
|
|
||
27
GSK
GSK
$117B
| – | – |
0
|
|
||
28
MoonLake Immunotherapeutics
MLTX
$1.32B
| – | – |
-441,000
|
|
||
|
29
PTC Therapeutics
PTCT
$6B
| – | – |
-1,500,000
|
|
||
30
Ionis Pharmaceuticals
IONS
$12.5B
| – | – |
-725,000
|
|
||
31
Qiagen
QGEN
$8.5B
| – | – |
-1,400,000
|
|
||
32
State Street SPDR S&P 500 ETF Trust
SPY
$720B
| – | – |
0
|
|
||
33
Sarepta Therapeutics
SRPT
$2.26B
| – | – |
-800,000
|
|
||
34
10x Genomics
TXG
$3.33B
| – | – |
-1,000,000
|
|
||
35
State Street SPDR S&P Biotech ETF
XBI
$8.94B
| – | – |
0
|
|